Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, REACH-2 study investigators

Open source

DOI: 10.1016/s1470-2045(18)30937-9
Published: 2019 Feb
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-18-30937-9,
  title = {Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Zhu AX and Kang YK and Yen CJ and Finn RS and Galle PR and Llovet JM and Assenat E and Brandi G and Pracht M and Lim HY and Rau KM and Motomura K and Ohno I and Merle P and Daniele B and Shin DB and Gerken G and Borg C and Hiriart JB and Okusaka T and Morimoto M and Hsu Y and Abada PB and Kudo M and REACH-2 study investigators},
  year = {2019},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(18)30937-9},
  url = {https://doi.org/10.1016/s1470-2045(18)30937-9}
}

RIS

TY  - JOUR
TI  - Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Zhu AX
AU  - Kang YK
AU  - Yen CJ
AU  - Finn RS
AU  - Galle PR
AU  - Llovet JM
AU  - Assenat E
AU  - Brandi G
AU  - Pracht M
AU  - Lim HY
AU  - Rau KM
AU  - Motomura K
AU  - Ohno I
AU  - Merle P
AU  - Daniele B
AU  - Shin DB
AU  - Gerken G
AU  - Borg C
AU  - Hiriart JB
AU  - Okusaka T
AU  - Morimoto M
AU  - Hsu Y
AU  - Abada PB
AU  - Kudo M
AU  - REACH-2 study investigators
PY  - 2019
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(18)30937-9
UR  - https://doi.org/10.1016/s1470-2045(18)30937-9
ER  -

APA

AX, Z., YK, K., CJ, Y., RS, F., PR, G., JM, L., E, A., G, B., M, P., HY, L., KM, R., K, M., I, O., P, M., B, D., DB, S., G, G., C, B., JB, H., T, O., M, M., Y, H., PB, A., M, K., & investigators, R. S. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(18)30937-9

Source records

pubmed · retrieved 2026-09-26T13:17:19.071Z